Does the media refer more to SRPT or CTMX?

In the previous week, Sarepta Therapeutics had 9 more articles in the media than CytomX Therapeutics. MarketBeat recorded 12 mentions for Sarepta Therapeutics and 3 mentions for CytomX Therapeutics. Sarepta Therapeutics' average media sentiment score of 0.57 beat CytomX Therapeutics' score of 0.10 indicating that Sarepta Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sarepta Therapeutics 5 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive CytomX Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer SRPT or EDIT?

In the previous week, Sarepta Therapeutics had 9 more articles in the media than Editas Medicine. MarketBeat recorded 12 mentions for Sarepta Therapeutics and 3 mentions for Editas Medicine. Sarepta Therapeutics' average media sentiment score of 0.57 beat Editas Medicine's score of 0.00 indicating that Sarepta Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sarepta Therapeutics 5 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Editas Medicine 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to SRPT or PRAX?

In the previous week, Sarepta Therapeutics had 10 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 12 mentions for Sarepta Therapeutics and 2 mentions for Praxis Precision Medicines. Sarepta Therapeutics' average media sentiment score of 0.57 beat Praxis Precision Medicines' score of 0.00 indicating that Sarepta Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sarepta Therapeutics 5 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Praxis Precision Medicines 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor SRPT or SYRE?

In the previous week, Sarepta Therapeutics had 6 more articles in the media than Spyre Therapeutics. MarketBeat recorded 12 mentions for Sarepta Therapeutics and 6 mentions for Spyre Therapeutics. Sarepta Therapeutics' average media sentiment score of 0.57 beat Spyre Therapeutics' score of 0.43 indicating that Sarepta Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sarepta Therapeutics 5 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Spyre Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer IONS or SRPT?

In the previous week, Sarepta Therapeutics had 7 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 12 mentions for Sarepta Therapeutics and 5 mentions for Ionis Pharmaceuticals. Sarepta Therapeutics' average media sentiment score of 0.57 beat Ionis Pharmaceuticals' score of 0.25 indicating that Sarepta Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ionis Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sarepta Therapeutics 5 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Sarepta Therapeutics (SRPT) Competitors

$17.58 +0.01 (+0.06%)

As of 10:52 AM Eastern

Compare

SRPT vs. CTMX, EDIT, PRAX, SYRE, and IONS

Should you buy Sarepta Therapeutics stock or one of its competitors? Sarepta Therapeutics's main competitors and comparable companies include CytomX Therapeutics (CTMX), Editas Medicine (EDIT), Praxis Precision Medicines (PRAX), Spyre Therapeutics (SYRE), and Ionis Pharmaceuticals (IONS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Sarepta Therapeutics compare to CytomX Therapeutics?

Sarepta Therapeutics (NASDAQ:SRPT) and CytomX Therapeutics (NASDAQ:CTMX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, risk and dividends.

Sarepta Therapeutics has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market. Comparatively, CytomX Therapeutics has a beta of 2.21, indicating that its stock price is 121% more volatile than the broader market.

Sarepta Therapeutics presently has a consensus target price of $23.81, suggesting a potential upside of 35.95%. CytomX Therapeutics has a consensus target price of $11.90, suggesting a potential upside of 355.07%. Given CytomX Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe CytomX Therapeutics is more favorable than Sarepta Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sarepta Therapeutics	6 Sell rating(s)	7 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.10
CytomX Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

86.7% of Sarepta Therapeutics shares are owned by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are owned by institutional investors. 6.9% of Sarepta Therapeutics shares are owned by company insiders. Comparatively, 3.8% of CytomX Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Sarepta Therapeutics had 9 more articles in the media than CytomX Therapeutics. MarketBeat recorded 12 mentions for Sarepta Therapeutics and 3 mentions for CytomX Therapeutics. Sarepta Therapeutics' average media sentiment score of 0.57 beat CytomX Therapeutics' score of 0.10 indicating that Sarepta Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sarepta Therapeutics	5 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
CytomX Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Sarepta Therapeutics has a net margin of -13.48% compared to CytomX Therapeutics' net margin of -435.21%. Sarepta Therapeutics' return on equity of -1.60% beat CytomX Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sarepta Therapeutics	-13.48%	-1.60%	-0.66%
CytomX Therapeutics	-435.21%	-38.46%	-30.33%

CytomX Therapeutics has lower revenue, but higher earnings than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sarepta Therapeutics	$2.20B	0.84	-$713.41M	-$2.90	N/A
CytomX Therapeutics	$76.20M	7.48	-$17.37M	-$0.50	N/A

Summary

CytomX Therapeutics beats Sarepta Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Sarepta Therapeutics compare to Editas Medicine?

Sarepta Therapeutics (NASDAQ:SRPT) and Editas Medicine (NASDAQ:EDIT) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, media sentiment, earnings, risk and institutional ownership.

86.7% of Sarepta Therapeutics shares are held by institutional investors. Comparatively, 71.9% of Editas Medicine shares are held by institutional investors. 6.9% of Sarepta Therapeutics shares are held by company insiders. Comparatively, 3.1% of Editas Medicine shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Sarepta Therapeutics has a beta of 0.38, indicating that its share price is 62% less volatile than the broader market. Comparatively, Editas Medicine has a beta of 2, indicating that its share price is 100% more volatile than the broader market.

Sarepta Therapeutics presently has a consensus target price of $23.81, suggesting a potential upside of 35.95%. Editas Medicine has a consensus target price of $5.80, suggesting a potential upside of 128.80%. Given Editas Medicine's stronger consensus rating and higher probable upside, analysts clearly believe Editas Medicine is more favorable than Sarepta Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sarepta Therapeutics	6 Sell rating(s)	7 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.10
Editas Medicine	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Sarepta Therapeutics had 9 more articles in the media than Editas Medicine. MarketBeat recorded 12 mentions for Sarepta Therapeutics and 3 mentions for Editas Medicine. Sarepta Therapeutics' average media sentiment score of 0.57 beat Editas Medicine's score of 0.00 indicating that Sarepta Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sarepta Therapeutics	5 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Editas Medicine	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Sarepta Therapeutics has a net margin of -13.48% compared to Editas Medicine's net margin of -157.32%. Sarepta Therapeutics' return on equity of -1.60% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sarepta Therapeutics	-13.48%	-1.60%	-0.66%
Editas Medicine	-157.32%	-196.63%	-38.17%

Editas Medicine has lower revenue, but higher earnings than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sarepta Therapeutics	$2.20B	0.84	-$713.41M	-$2.90	N/A
Editas Medicine	$40.52M	9.61	-$160.06M	-$0.75	N/A

Summary

Sarepta Therapeutics beats Editas Medicine on 9 of the 16 factors compared between the two stocks.

How does Sarepta Therapeutics compare to Praxis Precision Medicines?

Sarepta Therapeutics (NASDAQ:SRPT) and Praxis Precision Medicines (NASDAQ:PRAX) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings.

Sarepta Therapeutics has a beta of 0.38, suggesting that its share price is 62% less volatile than the broader market. Comparatively, Praxis Precision Medicines has a beta of 2.79, suggesting that its share price is 179% more volatile than the broader market.

In the previous week, Sarepta Therapeutics had 10 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 12 mentions for Sarepta Therapeutics and 2 mentions for Praxis Precision Medicines. Sarepta Therapeutics' average media sentiment score of 0.57 beat Praxis Precision Medicines' score of 0.00 indicating that Sarepta Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sarepta Therapeutics	5 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Praxis Precision Medicines	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Sarepta Therapeutics presently has a consensus target price of $23.81, suggesting a potential upside of 35.95%. Praxis Precision Medicines has a consensus target price of $612.42, suggesting a potential upside of 108.86%. Given Praxis Precision Medicines' stronger consensus rating and higher probable upside, analysts clearly believe Praxis Precision Medicines is more favorable than Sarepta Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sarepta Therapeutics	6 Sell rating(s)	7 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.10
Praxis Precision Medicines	2 Sell rating(s)	0 Hold rating(s)	15 Buy rating(s)	3 Strong Buy rating(s)	2.95

Praxis Precision Medicines has a net margin of 0.00% compared to Sarepta Therapeutics' net margin of -13.48%. Sarepta Therapeutics' return on equity of -1.60% beat Praxis Precision Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sarepta Therapeutics	-13.48%	-1.60%	-0.66%
Praxis Precision Medicines	N/A	-34.15%	-32.42%

Praxis Precision Medicines has lower revenue, but higher earnings than Sarepta Therapeutics. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Sarepta Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sarepta Therapeutics	$2.20B	0.84	-$713.41M	-$2.90	N/A
Praxis Precision Medicines	$8.55M	957.49	-$303.27M	-$12.93	N/A

86.7% of Sarepta Therapeutics shares are held by institutional investors. Comparatively, 67.8% of Praxis Precision Medicines shares are held by institutional investors. 6.9% of Sarepta Therapeutics shares are held by company insiders. Comparatively, 3.0% of Praxis Precision Medicines shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Sarepta Therapeutics beats Praxis Precision Medicines on 9 of the 17 factors compared between the two stocks.

How does Sarepta Therapeutics compare to Spyre Therapeutics?

Sarepta Therapeutics (NASDAQ:SRPT) and Spyre Therapeutics (NASDAQ:SYRE) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, media sentiment, dividends, valuation and earnings.

Spyre Therapeutics has a net margin of 0.00% compared to Sarepta Therapeutics' net margin of -13.48%. Sarepta Therapeutics' return on equity of -1.60% beat Spyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sarepta Therapeutics	-13.48%	-1.60%	-0.66%
Spyre Therapeutics	N/A	-30.74%	-22.23%

Sarepta Therapeutics presently has a consensus target price of $23.81, indicating a potential upside of 35.95%. Spyre Therapeutics has a consensus target price of $109.71, indicating a potential upside of 17.65%. Given Sarepta Therapeutics' higher probable upside, research analysts plainly believe Sarepta Therapeutics is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sarepta Therapeutics	6 Sell rating(s)	7 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.10
Spyre Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88

86.7% of Sarepta Therapeutics shares are owned by institutional investors. Comparatively, 80.4% of Spyre Therapeutics shares are owned by institutional investors. 6.9% of Sarepta Therapeutics shares are owned by company insiders. Comparatively, 15.7% of Spyre Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Sarepta Therapeutics had 6 more articles in the media than Spyre Therapeutics. MarketBeat recorded 12 mentions for Sarepta Therapeutics and 6 mentions for Spyre Therapeutics. Sarepta Therapeutics' average media sentiment score of 0.57 beat Spyre Therapeutics' score of 0.43 indicating that Sarepta Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sarepta Therapeutics	5 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Spyre Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Sarepta Therapeutics has a beta of 0.38, meaning that its share price is 62% less volatile than the broader market. Comparatively, Spyre Therapeutics has a beta of 3.1, meaning that its share price is 210% more volatile than the broader market.

Spyre Therapeutics has lower revenue, but higher earnings than Sarepta Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Sarepta Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sarepta Therapeutics	$2.20B	0.84	-$713.41M	-$2.90	N/A
Spyre Therapeutics	$890K	9,214.43	-$155.20M	-$1.95	N/A

Summary

Spyre Therapeutics beats Sarepta Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Sarepta Therapeutics compare to Ionis Pharmaceuticals?

Ionis Pharmaceuticals (NASDAQ:IONS) and Sarepta Therapeutics (NASDAQ:SRPT) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, analyst recommendations, institutional ownership and risk.

93.9% of Ionis Pharmaceuticals shares are held by institutional investors. Comparatively, 86.7% of Sarepta Therapeutics shares are held by institutional investors. 1.8% of Ionis Pharmaceuticals shares are held by company insiders. Comparatively, 6.9% of Sarepta Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Sarepta Therapeutics has a net margin of -13.48% compared to Ionis Pharmaceuticals' net margin of -64.76%. Sarepta Therapeutics' return on equity of -1.60% beat Ionis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ionis Pharmaceuticals	-64.76%	-111.08%	-17.41%
Sarepta Therapeutics	-13.48%	-1.60%	-0.66%

Ionis Pharmaceuticals currently has a consensus target price of $89.20, suggesting a potential upside of 102.99%. Sarepta Therapeutics has a consensus target price of $23.81, suggesting a potential upside of 35.95%. Given Ionis Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Ionis Pharmaceuticals is more favorable than Sarepta Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ionis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.73
Sarepta Therapeutics	6 Sell rating(s)	7 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.10

Ionis Pharmaceuticals has higher earnings, but lower revenue than Sarepta Therapeutics. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Sarepta Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ionis Pharmaceuticals	$944M	7.74	-$381.39M	-$3.46	N/A
Sarepta Therapeutics	$2.20B	0.84	-$713.41M	-$2.90	N/A

Ionis Pharmaceuticals has a beta of 0.38, suggesting that its share price is 62% less volatile than the broader market. Comparatively, Sarepta Therapeutics has a beta of 0.38, suggesting that its share price is 62% less volatile than the broader market.

In the previous week, Sarepta Therapeutics had 7 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 12 mentions for Sarepta Therapeutics and 5 mentions for Ionis Pharmaceuticals. Sarepta Therapeutics' average media sentiment score of 0.57 beat Ionis Pharmaceuticals' score of 0.25 indicating that Sarepta Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ionis Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sarepta Therapeutics	5 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Sarepta Therapeutics beats Ionis Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

Get Sarepta Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SRPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SRPT vs. The Competition

Export

Metric	Sarepta Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.85B	$3.93B	$7.22B	$13.08B
Dividend Yield	N/A	3.64%	2.53%	15.88%
P/E Ratio	-6.05	13.45	272.64	25.80
Price / Sales	0.84	1,294.15	607.49	90.99
Price / Cash	N/A	121.76	77.38	51.29
Price / Book	1.61	16.65	10.88	6.26
Net Income	-$713.41M	-$22.67M	$3.50B	$360.95M
7 Day Performance	-6.19%	-2.45%	-2.03%	-1.81%
1 Month Performance	-24.54%	-10.31%	-6.43%	-4.03%
1 Year Performance	-21.63%	21.98%	8.95%	2.18%

Sarepta Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SRPT Sarepta Therapeutics	3.0534 of 5 stars	$17.58 +0.1%	$23.81 +35.5%	-9.1%	$1.85B	$2.20B	N/A	835	Analyst Forecast
CTMX CytomX Therapeutics	1.9764 of 5 stars	$2.69 -0.4%	$11.90 +342.4%	-21.5%	$588.33M	$76.20M	N/A	69	Gap Up
EDIT Editas Medicine	1.776 of 5 stars	$2.51 -2.7%	$5.80 +131.1%	-29.0%	$396.24M	$40.52M	N/A	87
PRAX Praxis Precision Medicines	2.0649 of 5 stars	$285.65 +1.7%	$612.42 +114.4%	+441.1%	$7.84B	$8.55M	N/A	110
SYRE Spyre Therapeutics	2.3762 of 5 stars	$85.79 +0.1%	$109.69 +27.9%	+446.4%	$7.54B	$890K	N/A	112	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SRPT) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sarepta Therapeutics (SRPT) Competitors

SRPT vs. CTMX, EDIT, PRAX, SYRE, and IONS

How does Sarepta Therapeutics compare to CytomX Therapeutics?

Summary

How does Sarepta Therapeutics compare to Editas Medicine?

Summary

How does Sarepta Therapeutics compare to Praxis Precision Medicines?

Summary

How does Sarepta Therapeutics compare to Spyre Therapeutics?

Summary

How does Sarepta Therapeutics compare to Ionis Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRPT vs. The Competition

Sarepta Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sarepta Therapeutics (SRPT) Competitors

SRPT vs. CTMX, EDIT, PRAX, SYRE, and IONS

How does Sarepta Therapeutics compare to CytomX Therapeutics?

Which has more volatility & risk, SRPT or CTMX?

Do analysts rate SRPT or CTMX?

Do insiders and institutionals have more ownership in SRPT or CTMX?

Does the media refer more to SRPT or CTMX?

Is SRPT or CTMX more profitable?

Which has higher earnings & valuation, SRPT or CTMX?

Summary

How does Sarepta Therapeutics compare to Editas Medicine?

Do institutionals and insiders have more ownership in SRPT or EDIT?

Which has more risk & volatility, SRPT or EDIT?

Do analysts recommend SRPT or EDIT?

Does the media prefer SRPT or EDIT?

Is SRPT or EDIT more profitable?

Which has better earnings and valuation, SRPT or EDIT?

Summary

How does Sarepta Therapeutics compare to Praxis Precision Medicines?

Which has more risk & volatility, SRPT or PRAX?

Does the media refer more to SRPT or PRAX?

Do analysts prefer SRPT or PRAX?

Is SRPT or PRAX more profitable?

Which has better earnings & valuation, SRPT or PRAX?

Do insiders & institutionals believe in SRPT or PRAX?

Summary

How does Sarepta Therapeutics compare to Spyre Therapeutics?

Is SRPT or SYRE more profitable?

Do analysts recommend SRPT or SYRE?

Do institutionals & insiders believe in SRPT or SYRE?

Does the media favor SRPT or SYRE?

Which has more risk and volatility, SRPT or SYRE?

Which has better earnings & valuation, SRPT or SYRE?

Summary

How does Sarepta Therapeutics compare to Ionis Pharmaceuticals?

Do insiders and institutionals hold more shares of IONS or SRPT?

Is IONS or SRPT more profitable?

Do analysts recommend IONS or SRPT?

Which has higher valuation & earnings, IONS or SRPT?

Which has more volatility & risk, IONS or SRPT?

Does the media prefer IONS or SRPT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRPT vs. The Competition

Sarepta Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools